FDA approves Rigel Pharmaceuticals drug for rare bleeding disorder
The U.S. Food and Drug Administration (FDA) on Tuesday approved Rigel Pharmaceuticals Inc’s treatment for a rare bleeding disorder.
Rigel’s Tavalisse was approved to treat patients with immune thrombocytopenic purpura, a disease characterized by excessive bruising and bleeding caused by unusually low levels of platelets, which are integral to clotting.
(Reporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva)
ApprovesdrugFDAimmune thrombocytopenic purpurarare bleeding disorderRigel PharmaceuticalsTavalisseU.S. Food and Drug Administration
Source : REUTERSNext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd